Nominations sought for Paul Marks Prizes

April 01, 2001

New York, N.Y., April 2, 2001 - Nominations are now being sought for the first Paul Marks Prizes for Cancer Research. The prizes will recognize significant discoveries made by outstanding investigators up to the age of 45 at the time of the award.

"Memorial Sloan-Kettering has a unique opportunity to recognize young investigators whose research has advanced our understanding of cancer, either its biology or treatment," said Harold Varmus, President of Memorial Sloan-Kettering. "It is fitting that they honor the legacy of Paul Marks, a distinguished scientist and leader."

The prizes are named for Paul A. Marks, M.D., President Emeritus of Memorial Sloan-Kettering Cancer Center. They will recognize significant contributions to the basic understanding of the biological basis of cancer or to advancing the clinical care of persons with cancer through basic or clinical research.

The Paul Marks Prizes will be awarded to up to five investigators every other year, and the first recipients will be named in 2001.

The winners will be honored with a scientific symposium and dinner, and will share a cash award of $125,000.

Nominations should include a nominating letter that outlines the significance of the discovery for which the investigator should be recognized. This should be accompanied by a brief scientific biography of the candidate, a list of significant published papers and the candidate's curriculum vitae. Up to three supporting letters may also be submitted.

Nominations must be received by July 1, 2001. They should be sent to Linda Stevenson, Director, Research and Training Administration, Box 399, Memorial Sloan-Kettering Cancer Center, 1275 York Ave., New York, New York 10021.

Memorial Sloan Kettering Cancer Center

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to